Search

Displaying results 5701 - 5710 of 7017 in total
  1. Drug

    Acrizanib

    go.drugbank.com/drugs/DB16081
    Investigational

    Acrizanib is under investigation in clinical trial NCT02355028 (LHA510 Proof-of-concept Study as a Maintenance Therapy for Patients With Wet Age-related Macular Degeneration).

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    TP-252

    go.drugbank.com/drugs/DB17912
    Experimental

    TP-252 consists of magnesium L-lysinate bis-eicosapentaenoate, an ionizable salt of eicosapentaenoic acid (EPA), currently being investigated to treat familial adenomatous polyposis.[A259956]

    Synonyms: Magnesium, bis(l-lysinato-.kappa.n2,.kappa.o1)-, (t-4)-, (5z,8z,11z,14z,17z)-5,8,11,14,17-eicosapentaenoate (1:2)
  3. Drug

    ABBV-011

    go.drugbank.com/drugs/DB18622
    Investigational

    ABBV-011 is an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicin.

    Synonyms: an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicin
  4. Drug

    Gataparsen

    go.drugbank.com/drugs/DB05141
    Investigational

    LY2181308 is a solid. LY2181308 is directed against a molecular target called survivin. LY2181308 is known to target baculoviral IAP repeat-containing protein 5. … LY2181308 is an anti-sense oligonucleotide that potently downregulated survivin expression in human cancer cells derived from lung, colon, breast, prostate, ovary, cervix, skin and brain.

  5. Drug

    ND7001

    go.drugbank.com/drugs/DB05142
    Experimental

    It is a new type of antidepressant drug with anxiolytic activity. … ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid.

  6. Drug

    SB-249553

    go.drugbank.com/drugs/DB05285
    Experimental

    SB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. It is also under by GlaxoSmithKline to treat melanoma and lung cancer.

  7. Drug

    Befunolol

    go.drugbank.com/drugs/DB09013
    Experimental

    Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.

  8. Drug

    Risuteganib

    go.drugbank.com/drugs/DB14911
    Investigational

    Risuteganib is under investigation in clinical trial NCT02348918 (Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema).

  9. Drug

    UM-171

    go.drugbank.com/drugs/DB19449
    Investigational

    UM-171 is a pyrimidoindole derivative that is an agonist of ex vivo hematopoietic stem cell expansion and thus supports the expansion of hematopoietic stem cells.[A264868, A264873]

  10. Drug

    Rebaudioside A

    go.drugbank.com/drugs/DB15136
    Investigational

    Rebaudioside A is under investigation in clinical trial NCT03510624 (Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus).

    Synonyms: Rebaudioside A